Received On: 23/05/2014
Accepted On: 01/06/2014
Ravinandan, A. P., Basavanagowda, G. M., Jimmy, O. D., Kumar, S. L.
Sitagliptin is also known as Januvia which contains the active substance sitagliptin which is a member of a class of medicines called as dipeptidyl-peptidase-4 inhibitors (DPP-4 ) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus. Sitagliptin is the first dipeptidyl-peptidase-4 inhibitor which is used in the treatment of diabetes mellitus. It is very useful in improving β-cell function and reducing sugar level in the blood and also used in the special circumstances like chronic kidney diseases with appropriate dose adjustment. It is one of the most effective dipeptidyl-peptidase-4 inhibitor involved in reducing glycosylated hemoglobin (HbA1c), fasting as well as postprandial blood sugar levels when used as monotherapy or in combination with other oral hypoglycemic agents. In this review article we have summarized all the previous studies relevant to sitagliptin use in the clinical practice.
Sitagliptin, Dipeptidyl-Peptidase-4 Inhibitors, Type 2 Diabetes Mellitus, Glycosylated Hemoglobin
Cite This Article
Ravinandan, A. P., Basavanagowda, G. M., Jimmy, O. D., & Kumar, S. L. (2014). Review on Sitagliptin. International Journal for Pharmaceutical Research Scholars (IJPRS), 3(2), 577-581.